T. Rowe Price Investment Management, Inc. Centessa Pharmaceuticals PLC Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 401 shares of CNTA stock, worth $6,861. This represents 0.0% of its overall portfolio holdings.
Number of Shares
401
Previous 1,753,248
99.98%
Holding current value
$6,861
Previous $25.2 Million
99.98%
% of portfolio
0.0%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding CNTA
# of Institutions
128Shares Held
122MCall Options Held
655KPut Options Held
146K-
Medicxi Ventures Management (Jersey) LTD20MShares$342 Million74.33% of portfolio
-
Index Venture Life Associates Vi LTD St. Helier, Y99.96MShares$170 Million100.0% of portfolio
-
General Atlantic LLC New York, NY9.68MShares$166 Million4.43% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA8.4MShares$144 Million0.2% of portfolio
-
Janus Henderson Group PLC London, X06.53MShares$112 Million0.04% of portfolio
About Centessa Pharmaceuticals plc
- Ticker CNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,339,296
- Market Cap $1.61B
- Description
- Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...